Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$19.03
Change (%) Stock is Up 0.43 (2.31%)
Volume34,948
Data as of 05/24/17 11:11 a.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $19.03 with a 52 week high of $24.55 and a 52 week low of $7.07.
Recent NewsMore >>
DateTitle 
05/10/17REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
ROCKVILLE, Md., May 10, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In additi... 
Printer Friendly Version
05/09/17REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
On track to initiate dosing of patients in RGX-314 Phase I trial for wet AMD by mid-2017 and continuing enrollment of patients in RGX-501 Phase I/II trial for HoFH Interim trial updates for RGX-314 and RGX-501 anticipated by year-end 2017 $210 million in cash, cash equivalents and marketable securities as of March 31, 2017 ROCKVILLE, Md., May 09, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the ... 
Printer Friendly Version
05/04/17Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences
Preclinical data for RGX-314 program for the treatment of wet AMD to be presented at the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology, and the American Society for Gene and Cell Therapy Data support the active IND for RGX-314 Phase I clinical trial    ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative poten... 
Printer Friendly Version
05/02/17REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 9, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2017 and recent operational highlights. To access the live call by phone, dial (855) 422-... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
05/09/17
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.